HFS
TAK icon

Hantz Financial Services’s Takeda Pharmaceutical TAK Stock Holding History

Hantz Financial Services’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.32M Sell
269,650
-13,388
-5% -$222K 0.06% 215
2026
Q1 		$5.24M Buy
283,038
+29,560
+12% +$519K 0.08% 174
2025
Q4 		$3.95M Sell
253,478
-6,696
-3% -$95.7K 0.06% 229
2025
Q3 		$3.81M Buy
260,174
+32,933
+14% +$489K 0.06% 241
2025
Q2 		$3.51M Buy
227,241
+7,743
+4% +$114K 0.06% 249
2025
Q1 		$3.26M Buy
219,498
+327
+0.1% +$4.58K 0.06% 258
2024
Q4 		$2.9M Sell
219,171
-7,514
-3% -$103K 0.05% 280
2024
Q3 		$3.22M Buy
226,685
+6,967
+3% +$98.8K 0.06% 268
2024
Q2 		$2.84M Sell
219,718
-10,837
-5% -$143K 0.05% 275
2024
Q1 		$3.2M Buy
230,555
+3,298
+1% +$48K 0.06% 272
2023
Q4 		$3.24M Sell
227,257
-7,722
-3% -$110K 0.07% 274
2023
Q3 		$3.63M Buy
234,979
+3,383
+1% +$52.4K 0.09% 232
2023
Q2 		$3.64M Sell
231,596
-336
-0.1% -$5.5K 0.09% 232
2023
Q1 		$3.82M Buy
231,932
+45
+0% +$717 0.1% 218
2022
Q4 		$3.62M Sell
231,887
-5,101
-2% -$71.2K 0.11% 217
2022
Q3 		$3.07M Buy
236,988
+3,864
+2% +$53.7K 0.11% 216
2022
Q2 		$3.27M Buy
233,124
+9,439
+4% +$135K 0.11% 209
2022
Q1 		$3.2M Buy
223,685
+42,526
+23% +$624K 0.09% 228
2021
Q4 		$2.47M Buy
181,159
+13,416
+8% +$188K 0.07% 245
2021
Q3 		$2.75M Buy
167,743
+30,136
+22% +$506K 0.09% 222
2021
Q2 		$2.32M Buy
137,607
+22,020
+19% +$375K 0.08% 231
2021
Q1 		$2.11M Buy
+115,587
New +$2.08M 0.09% 230

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Hantz Financial Services's TAK Position: Q2 2026 in Review

Hantz Financial Services reduced its Takeda Pharmaceutical (TAK) stake by 4.7% in Q2 2026, selling an estimated $222K and leaving 269,650 shares worth $4.32M. The position accounts for 0.06% of the portfolio, ranked #215.

Hantz Financial Services first reported a position in TAK in Q1 2021 and has held it in 22 quarters since. The position peaked at $5.24M in Q1 2026. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Hantz Financial Services held 269,650 shares of Takeda Pharmaceutical worth $4.32M as of Q2 2026.
  • Hantz Financial Services sold 13,388 Takeda Pharmaceutical shares in Q2 2026, an estimated $222K.
  • Takeda Pharmaceutical made up 0.06% of Hantz Financial Services's portfolio in Q2 2026, its #215 holding.
  • Hantz Financial Services first reported a position in Takeda Pharmaceutical in Q1 2021 and has held it in 22 quarters since.
  • Hantz Financial Services's Takeda Pharmaceutical position peaked at $5.24M in Q1 2026.
  • 376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.